Translating breakthrough science into impactful new medicines
Syncona's early-stage innovation accelerator
About us
We unlock the potential of promising academic drug discovery by progressing it at pace.
We partner with leading academics to progress high potential breakthroughs towards drug development.
Our platform ensures that innovative scientific discoveries can grow and develop in an ever-more complex biotech landscape. Our team has the sector expertise, the operational infrastructure and the financial backing, through leading life science investor Syncona, to take ideas all the way to clinical readiness.
Our Platform
How we work to enable early science to thrive
Working with academics and pharma, we empower groundbreaking ideas, providing our programmes the required resources, the meaningful mentorship and the strategic support necessary to transform promising early-stage science into impactful biotech assets.
Early academic drug discovery projects
Programme entry
Securing groundbreaking early science discoveries from world-class scientists and key opinion leaders across the globe:
- Highest quality scientific hypotheses
- Innovative targets with strong linkage to mechanism of disease
- Novel therapeutic approaches
- Compelling areas of unmet need
Chemical matter
identified
Propulsion through the Slingshot platform
Programme acceleration
Moving at pace to accelerate initial ideas into robust candidate medicines:
- Proactive programme planning and risk management
- Multidisciplinary approach to programme progression; built around the founding science
- Structured milestones and programme governance
- A wealth of scientific and drug development advice, available from the outset
Development candidate identified
Individual programmes prepared for clinic
Programme development
High quality candidate medicines ready for clinical development:
- Robust target product profile
- Execution of clear, structured holistic drug development plan
- Delivery of compelling pre-clinical PoC data package
- Flexible models of partnership to progress through clinic and commercial launch
Our Partners
We bridge early-stage vision and late-stage reality
Our PORTFOLIO
We fast-track the best scientific discoveries
We work with the most promising scientific opportunities, focusing on identifying pathways that accelerate the journey from conceptual, early-stage hypotheses to tangible, breakthrough medicines.